Pasithea Therapeutics Corp. (KTTA)

US — Healthcare Sector
Peers: NTRBW  ZIVO  MNOV  ELYM  VRAX  BWV  REVB  HILS  KPRX  KZR  KRON  QNRX  RNXT  ABVC  INDP  BTTX  FBRX  PXMD 

Automate Your Wheel Strategy on KTTA

With Tiblio's Option Bot, you can configure your own wheel strategy including KTTA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol KTTA
  • Rev/Share 0.0
  • Book/Share 5.8695
  • PB 0.1653
  • Debt/Equity 0.0
  • CurrentRatio 3.8403
  • ROIC -0.2825

 

  • MktCap 7220270.0
  • FreeCF/Share -1.3863
  • PFCF -0.0024
  • PE -0.6003
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -1.0971

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering
KTTA
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

Pasithea Therapeutics (Nasdaq: KTTA) prices $5M public offering to fund clinical trials, R&D, and corporate initiatives; closing expected May 7, 2025.

Read More
image for news Pasithea Therapeutics Announces Pricing of $5 Million Public Offering
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004
KTTA
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

Pasithea Tx' PAS-004 shows up to 91% pERK inhibition in Phase 1 trial; one pancreatic cancer patient sees 4+ months stable disease and tumor shrinkage.

Read More
image for news Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

About Pasithea Therapeutics Corp. (KTTA)

  • IPO Date 2021-09-15
  • Website https://www.pasithea.com
  • Industry Biotechnology
  • CEO Dr. Tiago Reis Marques M.D., Ph.D.
  • Employees 4
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.